OyaGen developed Oya1 (aka sangivamycin and exclusively licensed to Tonix Pharmaceuticals as TNX-3500) in collaboration with NIH/NIAID as a highly potent compound that prevents the spread of infection of Coronaviruses, Ebola, Lassa virus and Pox virus. OyaGen owns the patent rights to TNX-3500 (aka sangivamycin). Specifically, OyaGen has seven patents pending for this highly potent compound that prevents the spread of infection by Coronaviruses, Ebola, Lassa virus and Pox virus. The compound was taken through late-stage preclinical development by OyaGen prior to exclusively licensing it to Tonix Pharmaceuticals Inc, a clinical stage company who will develop TNX-3500 for clinical trials and commercialization. TNX-3500 has been safely administered to nonhuman primates and humans in the 1960’s during the war on cancer but was abandoned as being ineffective against cancer. TNX-3500 is a broad-spectrum antiviral and has excellent drug-like ADMET properties and higher potency relative to remdesivir in live virus studies. TNX-3500 antiviral activity is additive with remdesivir when the drugs are used in combination as shown in our publication in JCI Insight (10.1172/jci.insight.153165). TNX-3500 potential as a preventative for viral infections is suggested by its long half-life in tissues. TNX-3500 holds potential as a much needed, life-saving therapeutic approach for those who cannot benefit from a vaccine or will not take a vaccine.